金贝口服液治疗新型冠状病毒肺炎(COVID-19)疗效回顾性分析  

Clinical Efficacy of Jinbei Oral Liquid in the Treatment of COVID-19 by Retrospective Analysis

作　　者：李雅慧[1] 张爱均 王俊凯 张应刚 索小英 王军强[1] 张良棕 孟兆青 Li Yahui;Zhang Aijun;Wang Junkai;Zhang Yinggang;Suo Xiaoying;Wang Junqiang;Zhang Liangzong;Meng Zhaoqing(The Second Affiliated Hospital of Shandong University of Traditional Chinese Medicine,Jinan 250100;Shandong Hongjitang Pharmaceutical Group Co.,Ltd.,Jinan 250103;Zibo Zhangdian District Hospital of Traditional Chinese Medicine,Zibo 255022;Huantai Hospital of Traditional Chinese Medicine,Zibo 256400;Dongying Peopled Hospital,Dongying 257000;Shandong Provincial Technology Innovation Center of Traditional Chinese Medicine Treatment of Respiratory Diseases,Jinan 250103)

机构地区：[1]山东中医药大学第二附属医院,济南250100 [2]山东宏济堂制药集团股份有限公司,济南250103 [3]淄博市张店区中医院,淄博255022 [4]桓台县中医医院,淄博256400 [5]东营市人民医院,东营257000 [6]山东省中医药治疗呼吸系统疾病技术创新中心,济南250103

出　　处：《中药药理与临床》2021年第5期7-10,共4页Pharmacology and Clinics of Chinese Materia Medica

基　　金：国家“重大新药创制”科技重大专项项目(编号:2014ZX09509001-002);年度山东省重点研发计划(重大科技创新工程)(编号:2020CXGC010505);山东省第四批技术创新项目(编号:201741901259);济南市科学技术发展计划第一批(新冠肺炎防控应急专项)项目(编号202001006-1);泉城“5150”引才倍增计划创新人才项目;山东省中医药治疗呼吸系统疾病技术创新中心平台项目。

摘　　要：目的:回顾性分析金贝口服液(Jinbei Oral Liquid,Jb.L)联合化学药品治疗新型冠状病毒肺炎(COVID-19)的临床疗效。方法:收集2020年2月~4月就诊的96例符合新型冠状病毒肺炎(轻型、普通型)患者临床资料,所收集患者经中医辨证均为肺脾两虚、邪热伤津病人,其中金贝口服液联合化药常规治疗患者50例为试验组,临床常规治疗(未使用金贝口服液)患者46例为对照组,对患者基本信息、中医症状、实验室检查、治疗效果等进行统计分析,比较两组患者主要症状(咳嗽、乏力、发热)的消失时间,核酸检测转阴天数、转阴率,治疗有效天数及临床恢复率等。结果:两组患者性别、身高、体重、疾病诊断、脉搏等基本信息均无统计学意义(P>0.05)。15 d治疗后患者在治疗过程中一次发热率、乏力消失天数均值、咳嗽消失天数均值、核酸转阴天数均值、临床治疗有效天数均值,两组间差异均有统计学意义(P<0.05),试验组优于对照组;核酸转阴率、临床恢复天数均值,两组间差异无统计学意义(P>0.05)。结论:金贝口服液联合化药治疗新型冠状病毒肺炎较常规治疗组可缩短患者核酸转阴时间,乏力、咳嗽症状消失时间,降低治疗过程中患者体温波动,缩短新型冠状病毒肺炎患者治疗有效天数。Objective:To analyze the clinical efficacy of Jinbei Oral Liquid(Jb.L)combined with western medicine in the treatment of coronavirus disease 2019(COVID-19).Methods:The clinical data from 96 COVID-19 patients with mild or common COVID-19 admitted to Wuhan third hospital from February to April 2020 were screened out.According to TCM syndrome differentiation,the syndromes were characterized as Feipiliangxu and Xiereshangjin type.50 patients were selected as Jb.L experimental group who were treated with Jb.L combined with western medicine,46 patients were selected as the control group who were given the conventional treatment.The basic information,TCM symptom,the data of laboratory test and the clinical efficacy were statistically analyzed.The disappearance rate of main symptoms(cough,fatigue and fever),the negative conversion time of nucleic acid,the negative conversion rate,the time to effective treatment and clinical recovery rate were compared between the two groups.Results:There were no statistically significant difference in the gender,the body height,the body weight,the diagnosis and the pulse rate between the two groups(P>0.05).After 15 days of treatment,compared with the control group,the fever rate,the time of fatigue disappearance,the time of cough disappearance,the negative conversion time of nucleic acid and the days of clinical effective treatment were improved in Jb.L experimental group,there were statistically significant difference(P<0.05),while there were no statistically significant difference in the negative conversion rate and the clinical recovery days(P>0.05).Conclusion:Jb.L combined with western medicine can shorten the negative conversion time of nucleic acid,the disappearance time of fatigue and cough,and it also reduces the abnormal fluctuation of body temperature during the treatment and shortens the days of effective treatment for COVID-19.

关 键 词：新型冠状病毒肺炎 金贝口服液 回顾性研究 

分 类 号：R259[医药卫生—中西医结合]